首页> 外文OA文献 >Discovery and characterization of a novel potent type II native and mutant BCR-ABL inhibitor (CHMFL-074) for Chronic Myeloid Leukemia (CML)

【2h】

Discovery and characterization of a novel potent type II native and mutant BCR-ABL inhibitor (CHMFL-074) for Chronic Myeloid Leukemia (CML)

机译：用于慢性髓性白血病（CML）的新型有效型II天然和突变体BCR-ABL抑制剂（CHMFL-074）的发现和表征

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Feiyang Liu; Beilei Wang; Qiang Wang; Ziping Qi; Cheng Chen; Lu-Lu Kong; Ji-Yun Chen; Xiaochuan Liu; Aoli Wang; Chen Hu; Wenchao Wang; Huiping Wang; Fan Wu; Yanjie Ruan; Shuang Qi; Juan Liu; Fengming Zou; Zhenquan Hu; Wei Wang; Li Wang; Shanchun Zhang; Cai-Hong Yun; Zhimin Zhai; Jing Liu; Qingsong Liu;
展开▼
作者单位

展开▼
年度 2016
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Discovery and characterization of a novel highly potent and selective type II native and drug-resistant V299L mutant BCR-ABL inhibitor (CHMFL-ABL-039) for Chronic Myeloid Leukemia (CML) [J] . Wu Jiaxin, Wang Aoli, Li Xixiang, Cancer biology & therapy . 2019,第4a6期

机译：对慢性髓性白血病（CML）的新型高效和选择性II天然和耐药V299L突变体BCR-ABL-039）的发现和表征
2. Discovery of a Candidate Containing an (S)-3,3-Difluoro-1-(4-methylpiperazin-1-yl)-2,3-dihydro-1H-inden Scaffold as a Highly Potent Pan-Inhibitor of the BCR-ABL Kinase Including the T315I-Resistant Mutant for the Treatment of Chronic Myeloid Leukemia [J] . Zhang Dongfeng, Li Peng, Gao Yongxin, Journal of Medicinal Chemistry . 2021,第11期

机译：发现含有（S）-3-二氟-1-（4-甲基皮酶-1-基）-2,3-二氢-1-INDEN支架的候选物作为BCR-ABL的高效泛抑制剂激酶，包括T315i抗性突变体用于治疗慢性骨髓性白血病
3. SHC004-221A1, a novel tyrosine kinase, potently inhibits T315I mutant BCR-ABL in chronic myeloid leukemia [J] . Duowei Wang, Yan Zheng, Jiaying Li, European Journal of Pharmacology: An International Journal . 2017,第期

机译：新型酪氨酸激酶SHC004-21A1，效果抑制慢性髓性白血病中的T315i突变体BCR-ABL
4. Absolute quantification for clinical-resistant BCR-ABL mutants from Chronic myeloid leukemia (CML) [C] . Jung Ok Park, Gum Yong Kang, Sun Kyu Choi, ASMS Conference on Mass Spectrometry and Allied Topics . 2008

机译：慢性骨髓白血病（CML）的临床抗性BCR-ABL突变体的绝对量化
5. Characterization of hemopoietic stem cells in chronic myeloid leukemia (CML). [D] . Udomsakdi, Chirayu. 1992

机译：慢性粒细胞白血病（CML）中造血干细胞的特征。
6. Discovery and characterization of a novel highly potent and selective type II native and drug-resistant V299L mutant BCR-ABL inhibitor (CHMFL-ABL-039) for Chronic Myeloid Leukemia (CML) [O] . Jiaxin Wu, Aoli Wang, Xixiang Li, 2019

机译：发现和表征一种新型的强效和选择性II型天然和耐药V299L突变型BCR-ABL抑制剂（CHMFL-ABL-039）用于治疗慢性粒细胞白血病（CML）
7. Discovery of 2((3-Amino-4-methylphenyl)amino)N(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-ABL-053) as a Potent, Selective, and Orally Available BCR-ABL/SRC/p38 Kinase Inhibitor for Chronic Myeloid Leukemia [O] . -1

机译：发现2（（3-氨基-4-甲基苯基）氨基）N（2-甲基-5-（3-（三氟甲基）苯甲酰氨基）苯基）-4-（甲基氨基）嘧啶-5-甲酰胺（CHMFL-ABL-053 ）作为慢性髓性白血病的有效，选择性和口服的BCR-ABL / SRC / P38激酶抑制剂

Discovery and characterization of a novel potent type II native and mutant BCR-ABL inhibitor (CHMFL-074) for Chronic Myeloid Leukemia (CML)

著录项

引文网络

相似文献

相关主题

期刊订阅